Shots:

• The collaboration will extend in 2022 for an additional 3yrs. Calico will lead R&D until 2025 & will advance projects into P-IIa through 2030 while AbbVie will support Calico in its early R&D efforts- following the completion of P-IIa studies- will get the option to manage late-stage development & commercial activities
• Both the companies will equally share costs & profits and each of them will contribute $500M to the collaboration. This marks the second extension of the collaboration originally established in 2014
• Since 2014- the collaboration has produced 20+ early-stage programs addressing disease across I-O and neurodegeneration and has yielded new insights into the biology of aging

  | Ref: Abbvie | Image: abbvie